

Product Contents

Product	Volume
NanoSpark™ EVEN-T Soluble T-Cell Activator	1 mL

NanoSpark EVEN-T Soluble T-Cell Activator is provided in 1 mL vials. The activator is suspended in phosphate buffered saline glycerol. Store at -80 °C long-term. Once thawed, store at 4 °C protected from light for up to one month.

Description

Nanotein's NanoSpark EVEN-T Soluble T Cell Activator is engineered to activate and expand an enriched human T lymphocyte population. NanoSpark EVEN-T Soluble T Cell Activator is a self-assembling protein nanoparticle with anti-CD3 and anti-CD28 antibodies conjugated to the surface mixed with a proprietary additive. The biophysical display of anti-CD3 and anti-CD28 antibodies on the nanoparticle surface of EVEN-T leads to strong primary and co-stimulatory signals that uniquely activate and expand T cells. NanoSpark EVEN-T Soluble T Cell Activator is designed for use with cytokine-supplemented T cell expansion medium.

Applications

Nanotein's NanoSpark EVEN-T Soluble T Cell Activator is intended for *ex vivo* activation and expansion of CD3⁺ T Lymphocytes or human resting T cells from peripheral blood mononuclear cells (PBMCs).

Recommended Materials Not Provided

The following materials and equipment are recommended for use with NanoSpark EVEN-T Soluble T-Cell Activator.

- * Fresh or cryopreserved CD3⁺ T Lymphocytes or PBMCs (StemCell Cat. #70024 or 70025)
- * CellGenix GMP TCM (Sartorius Cat. # 20814-0500)
- * PRIME-XV T Cell Expansion XSFM (Irvine Scientific Cat. # 91141)
- * TheraPEAK T-VIVO Cell Culture Medium (Lonza Cat.# BP12-970Q)
- * Recombinant Human IL-7 (StemCell Cat. #78053)
- * Recombinant Human IL-15 (StemCell Cat. #78031)
- * Sterile culture vessels
- * Flow Cytometer
- * Fluorophore-conjugated antibodies for flow cytometer characterization

Protocol

The following is a general protocol for using NanoSpark EVEN-T Soluble T Cell Activator. Optimization may be necessary depending on your experimental objectives.

Fresh cells

1. Day 0 – Activation
 - a. Exchange CD3⁺ T cells or PBMCs into culture media.
 - b. Count cells & seed at 1 x 10⁶ cells/mL in culture media.
 - c. To activate cells, add 4-10 µL of NanoSpark EVEN-T Soluble T Cell Activator for every mL of cell suspension ***MEDIA DEPENDENT (see Figure 1)**. (e.g., 32-100 µL of Activator for 8 mL of cell suspension).
 - d. Add IL-7 and IL-15 to culture media for a 10 ng/mL final concentration of each.
 - e. Incubate cells at 37 °C and 5% CO₂ in a humidified incubator.
2. Transduction (OPTIONAL)
 - a. 24-72 hours after activator addition, apply viral vector for ~24-48 hours.
3. Electroporation (OPTIONAL)
 - a. 72 hours after activator addition, electroporate according to manufacturer's instructions.
 - b. Add cells to media containing 5% human serum for better recovery.
4. Cell Expansion & Maintenance
 - a. **Ensure activator is in culture media (conditioned or fresh) for at least ~72 hours and can be left in throughout the expansion.**
 - b. Every 2-3 days monitor and/or count the cells for viability & density adjustment.
 - c. Add fresh culture medium supplemented with 10 ng/mL IL-7 and 10 ng/mL IL-15 to the appropriate cell density for your specific application.
 - d. Incubate cells at 37 °C and 5% CO₂ in a humidified incubator.
 - e. Repeat these maintenance steps until the desired cell number is reached or up to 14 days after initial activation.

NOTE: Be sure to add fresh culture media supplemented with IL-7 and IL-15 every 3 days. For optimization in your specific setup, **consider using activator between 5 - 10 µL per mL (see Figure 1)*.**

[ALT] Cryopreserved Cells

1. Day 0
 - a. Thaw and exchange CD3⁺ T cells or PBMCs into culture media.
 - b. Count cells & seed at 1 x 10⁶ cells/mL in culture media.

c. Incubate cells at 37 °C and 5% CO₂ for ~2-3 hours in a humidified incubator.

2. [Follow Steps 1c – 4e under “Fresh cells” above].

*** Serum addition may further enhance percentage of CD4⁺ T cells – Optimization Required ***

*All Serum-Free




Figure 1. Increasing amounts of EVEN-T shifts the CD4⁺:CD8⁺ ratio towards CD4⁺s with media-dependent differences in functional windows. NanoSpark EVEN-T Soluble T-Cell Activator was added to CD3⁺ negatively selected human peripheral blood T cells cultured in CellGenix’s TCM, Lonza’s T-Vivo, or FujiFilm’s Prime-XV serum-free media supplemented with IL-7 and IL-15 and compared to NanoSpark STEM-T Soluble T-Cell Activator. Cells were expanded for 10 days and analyzed on a flow cytometer on days 0, 7, and 10. Cells were labeled with CD4⁺, CD8⁺, CD45RA, CCR7, and CD95 fluorescent antibodies

(Schmueck-Henneresse et al 2017). Expansion with NanoSpark EVEN-T Soluble T-Cell Activator modulates the expansion to shift the expanded T cell profile towards CD4⁺ T cells in a dose-dependent manner, effectively allowing the user to select a CD4⁺:CD8⁺ T cell ratio at the outset of expansion.

Legal Notices

Use of this product is subject to, and constitutes acceptance of, the following terms and conditions.

The product is licensed to customer for internal research use only. Customer shall not (a) sell, distribute, rent, lease, lend, sublicense, or otherwise commercialize the product or any accompanying materials; (b) use the product for any therapeutic, diagnostic or other clinical purposes; (c) reverse engineer the product or any accompanying materials; (d) publicly release or disclose the results of, development, or evaluation of the product; or (e) remove or alter any proprietary notices or labels on or in the product or any accompanying materials.

THE PRODUCT AND ANY ACCOMPANYING MATERIALS ARE PROVIDED ON AN "AS IS" BASIS WITHOUT ANY REPRESENTATIONS OR WARRANTIES OF ANY KIND. NANOTEIN AND ITS LICENSORS DISCLAIM ANY AND ALL WARRANTIES AND REPRESENTATIONS (EXPRESS OR IMPLIED, ORAL OR WRITTEN) WITH RESPECT TO THE PRODUCT AND ANY ACCOMPANYING MATERIALS, WHETHER ALLEGED TO ARISE BY OPERATION OF LAW, BY REASON OF CUSTOM OR USAGE IN THE TRADE, BY COURSE OF DEALING OR OTHERWISE, INCLUDING ANY AND ALL (A) WARRANTIES OF MERCHANTABILITY, (B) WARRANTIES OF FITNESS OR SUITABILITY FOR ANY PURPOSE (WHETHER OR NOT NANOTEIN OR ITS LICENSORS KNOW, HAVE REASON TO KNOW, HAVE BEEN ADVISED OR ARE OTHERWISE AWARE OF ANY SUCH PURPOSE), AND (C) WARRANTIES OF NONINFRINGEMENT OR CONDITION OF TITLE. CUSTOMER ACKNOWLEDGES AND AGREES THAT IT HAS NOT RELIED ON ANY WARRANTIES REGARDING THE PRODUCT OR ACCOMPANYING MATERIALS, THAT IT HAS READ AND UNDERSTOOD ALL DOCUMENTATION PROVIDED WITH THE PRODUCT, AND THAT CUSTOMER IS SOLELY RESPONSIBLE FOR DETERMINING IF THE NANOTEIN MATERIALS ARE SUITABLE FOR CUSTOMER'S PARTICULAR PURPOSE AND APPLICATION. CUSTOMER HEREBY ASSUMES ALL RISK ASSOCIATED WITH USE OF THE PRODUCT AND/OR ACCOMPANYING MATERIALS TO THE FULLEST EXTENT PERMITTED BY LAW.

©2022 Nanotein Technologies, Inc. All rights reserved including images and graphics. All trademarks are property of Nanotein Technologies, Inc. and/or their respective owners.